ATE402956T1 - Neue, mhc klasse ii assoziierte peptide - Google Patents

Neue, mhc klasse ii assoziierte peptide

Info

Publication number
ATE402956T1
ATE402956T1 AT03748078T AT03748078T ATE402956T1 AT E402956 T1 ATE402956 T1 AT E402956T1 AT 03748078 T AT03748078 T AT 03748078T AT 03748078 T AT03748078 T AT 03748078T AT E402956 T1 ATE402956 T1 AT E402956T1
Authority
AT
Austria
Prior art keywords
mhc class
antigenic peptides
associated peptides
tumors
present
Prior art date
Application number
AT03748078T
Other languages
English (en)
Inventor
Harald Kropshofer
Till Roehn
Anne Vogt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE402956T1 publication Critical patent/ATE402956T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03748078T 2002-10-02 2003-09-24 Neue, mhc klasse ii assoziierte peptide ATE402956T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022224 2002-10-02

Publications (1)

Publication Number Publication Date
ATE402956T1 true ATE402956T1 (de) 2008-08-15

Family

ID=32049974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03748078T ATE402956T1 (de) 2002-10-02 2003-09-24 Neue, mhc klasse ii assoziierte peptide

Country Status (9)

Country Link
US (2) US20050202009A1 (de)
EP (1) EP1549673B1 (de)
JP (1) JP2006518982A (de)
CN (3) CN101260154A (de)
AT (1) ATE402956T1 (de)
AU (1) AU2003267401A1 (de)
CA (1) CA2498854A1 (de)
DE (1) DE60322559D1 (de)
WO (1) WO2004031230A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097828A2 (en) * 2006-01-06 2007-08-30 The Johns Hopkins University Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay
KR101543624B1 (ko) * 2007-08-20 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｆｏｘｍ１ 펩티드 및 이를 포함하는 약학적 조성물
JP5147852B2 (ja) 2007-10-18 2013-02-20 株式会社メディカル・プロテオスコープ 手術後の予後を推定する方法及び診断キット
WO2010129537A1 (en) * 2009-05-05 2010-11-11 The Johns Hopkins University Phosphopeptides as melanoma vaccines
NZ597724A (en) * 2009-07-24 2013-10-25 Rhode Island Hospital Dendritic cell vaccines for asparaginyl-beta-hydroxylase expressing tumors
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
JP2017528430A (ja) * 2014-07-17 2017-09-28 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
AU2017222461A1 (en) * 2016-02-22 2018-08-30 Oceanside Biotechnology Neoantigen compositions and methods of using the same in immunooncotherapy
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7493497B2 (ja) * 2018-06-19 2024-05-31 フォンダッツィオーネ・テレソン・エティエッセ 操作された樹状細胞の生産及びその使用
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン６結合分子およびその使用
GB202006760D0 (en) * 2020-05-07 2020-06-24 Univ Helsinki Bioinformatics
CN112618712A (zh) * 2021-01-21 2021-04-09 武汉轻工大学 一种含波形蛋白的佐剂及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies

Also Published As

Publication number Publication date
JP2006518982A (ja) 2006-08-24
EP1549673A2 (de) 2005-07-06
CN101185754A (zh) 2008-05-28
EP1549673B1 (de) 2008-07-30
CN101260154A (zh) 2008-09-10
CA2498854A1 (en) 2004-04-15
AU2003267401A1 (en) 2004-04-23
CN100347191C (zh) 2007-11-07
US20070073042A1 (en) 2007-03-29
WO2004031230A3 (en) 2005-01-13
WO2004031230A2 (en) 2004-04-15
DE60322559D1 (de) 2008-09-11
US20050202009A1 (en) 2005-09-15
CN1688602A (zh) 2005-10-26

Similar Documents

Publication Publication Date Title
DE60322559D1 (de) Neue, mhc klasse ii assoziierte peptide
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1107042T1 (el) Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων
PT2092938E (pt) Péptidos derivados de survivina e a sua utilização
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
CY1110862T1 (el) Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
EP2193804A3 (de) Rekombinantes Adenylat-Cyclase-Toxin von Bordetella induziert T-Zell-Antworten gegen tumorale Antigene
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
WO2023192820A3 (en) Tumor-associated antigens in brain tumors
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου
ATE243760T1 (de) Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen- karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen
ATE480250T1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
EA202192991A1 (ru) Новые раковые антигены и сопутствующие способы
ATE459640T1 (de) Sich an die protein phosphatase 2a bindende peptide und sie kodierende polynukleotide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties